Sandbox/Alejandro: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 24: Line 24:
<div style="border-radius: 0 0 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #A1BCDD; text-align: center;">
<div style="border-radius: 0 0 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #A1BCDD; text-align: center;">
<font color="#FFF">
<font color="#FFF">
'''Non-purulent Cellulitis'''
'''Non-Purulent Cellulitis'''
</font>
</font>
</div>
</div>
Line 81: Line 81:
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #A1BCDD; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Non-Purulent Cellulitis}}
|-
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Parental Regimen}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Parental Regimen}}
|-
|-
Line 112: Line 114:
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #A1BCDD; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Non-Purulent Cellulitis}}
|-
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Parental Regimen}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Parental Regimen}}
|-
|-
Line 142: Line 146:
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #A1BCDD; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Purulent Cellulitis}}
|-
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Parental Regimen}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Parental Regimen}}
|-
|-
Line 172: Line 178:
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #A1BCDD; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Purulent Cellulitis}}
|-
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Parental Regimen}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Parental Regimen}}
|-
|-
Line 203: Line 211:
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #A1BCDD; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Complicated Cellulitis}}
|-
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Parental Regimen}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Parental Regimen}}
|-
|-
Line 236: Line 246:
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #A1BCDD; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Complicated Cellulitis}}
|-
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Parental Regimen}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Parental Regimen}}
|-
|-
Line 271: Line 283:
* [[Doxycycline]] is '''NOT''' recommended for children <8 years of age.
* [[Doxycycline]] is '''NOT''' recommended for children <8 years of age.
* Studies have shown an increase in treatment failure with [[TMP-SMX]] compared to other agents for [[cellulitis]] in children, reflecting [[TMP-SMX]] less action against [[Group A streptococcus]].<ref name="pmid19470525">{{cite journal| author=Elliott DJ, Zaoutis TE, Troxel AB, Loh A, Keren R| title=Empiric antimicrobial therapy for pediatric skin and soft-tissue infections in the era of methicillin-resistant Staphylococcus aureus. | journal=Pediatrics | year= 2009 | volume= 123 | issue= 6 | pages= e959-66 | pmid=19470525 | doi=10.1542/peds.2008-2428 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19470525  }} </ref>
* Studies have shown an increase in treatment failure with [[TMP-SMX]] compared to other agents for [[cellulitis]] in children, reflecting [[TMP-SMX]] less action against [[Group A streptococcus]].<ref name="pmid19470525">{{cite journal| author=Elliott DJ, Zaoutis TE, Troxel AB, Loh A, Keren R| title=Empiric antimicrobial therapy for pediatric skin and soft-tissue infections in the era of methicillin-resistant Staphylococcus aureus. | journal=Pediatrics | year= 2009 | volume= 123 | issue= 6 | pages= e959-66 | pmid=19470525 | doi=10.1542/peds.2008-2428 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19470525  }} </ref>
==References==
{{Reflist|2}}

Revision as of 19:33, 23 May 2014

Empiric TherapyAdapted from Clinical Practice Guidelines CID 2011[1] and Guidelines for Skin and Soft-Tissue Infections CID 2005[2]

▸ Click on the following categories to expand treatment regimens.

Cellulitis

Non-Purulent Cellulitis

  ▸  Adults

  ▸  Children age >28 days

Purulent Cellulitis

  ▸  Adults

  ▸  Children age >28 days

Complicated Cellulitis†

  ▸  Adults

  ▸  Children age >28 days


Non-Purulent Cellulitis
Parental Regimen
Preferred Regimen
Oxacillin 2g IV q4h
OR
Nafcillin 2g IV q4h
Alternative Regimen (penicillin-allergic patients)
Cefazolin 1-2 g IV q8h (without immediate hypersensitivity reactions)
OR
Clindamycin 600 mg IV q8h (with immediate hypersensitivity reactions)
Oral Regimen
Preferred Regimen
Dicloxacillin 500 mg orally q6h
Alternative Regimen (penicillin-allergic patients)
Cephalexin 500 mg orally q6h (without immediate hypersensitivity reactions)
OR
Doxycycline 100 mg orally q12h
OR
Minocycline 100 mg orally q12h
OR
Trimethoprim-sulfamethoxazole 1 or 2 double-strength tablets orally q12h
OR
Clindamycin 300–450 mg orally q8h
Non-Purulent Cellulitis
Parental Regimen
Preferred Regimen
Oxacillin 100-150 mg/kg per day IV in 4 doses
OR
Nafcillin 100-150 mg/kg per day IV in 4 doses
Alternative Regimen (penicillin-allergic patients)
Cefazolin 50 mg/kg per day IV in 3 doses (without immediate hypersensitivity reactions)
OR
Clindamycin 25-40 mg/kg per day IV in 3 doses(with immediate hypersensitivity reactions)
OR
Trimethoprim-sulfamethoxazole 8–12 mg/kg IV in 4 doses
Oral Regimen
Preferred Regimen
Dicloxacillin 25 mg/kg per day orally in 4 doses
Alternative Regimen (penicillin-allergic patients)
Cephalexin 25 mg/kg per day orally in 4 doses(without immediate hypersensitivity reactions)
OR
Clindamycin 10-20 mg/kg per day orally in 4 doses
OR
Trimethoprim-sulfamethoxazole 8–12 mg/kg orally in 2 doses
Purulent Cellulitis
Parental Regimen
Preferred Regimen
Vancomycin 30 mg/kg/dose IV q12h
Alternative Regimen
Linezolid 600 mg IV q12h
OR
Clindamycin 600 mg IV q8h
OR
Daptomycin 4 mg/kg IV q24h
Oral Regimen
Preferred Regimen
Linezolid 600 mg orally q12h
Alternative Regimen
Clindamycin 300 to 450 mg q8h
OR
Linezolid 600 mg orally q12h
OR
Minocycline 100 mg orally q12h
OR
Doxycycline 100 mg orally q12h
OR
Trimethoprim-sulfamethoxazole 1 or 2 double-strength tablets orally q12h
Purulent Cellulitis
Parental Regimen
Preferred Regimen
Vancomycin 40 mg/kg/day IV in 4 divided doses
Alternative Regimen
Linezolid 10 mg/kg IV q12h
OR
Clindamycin 25–40 mg/kg/day IV in 3 divided dose
OR
Trimethoprim-sulfamethoxazole 8–12 mg/kg/day (based on the trimethoprim component) IV in 4 divided doses
Oral Regimen
Preferred Regimen
Linezolid 10 mg/kg orally q12h
Alternative Regimen
Clindamycin 10-20 mg/kg per day orally divided in 3 doses
OR
Trimethoprim-sulfamethoxazole 8-12 mg trimethoprim component/kg per day orally divided in 2 doses
Complicated Cellulitis
Parental Regimen
Preferred Regimen
Vancomycin 15-20 mg/kg IV q8-12h
OR
Linezolid 600 mg IV q12h
OR
Daptomycin 4mg/kg IV q24h
OR
Telavancin 10mg/kg IV q24h
Alternative Regimen
Clindamycin 600 mg IV q8h
Oral Regimen
Preferred Regimen
Linezolid 600 mg PO q12h
Alternative Regimen
Clindamycin 600 mg PO q8h
Complicated cellulitis refers to a deeper soft-tissue infections and the association with necrotizing fasciitis, septic arthritis, or osteomyelitis
Complicated Cellulitis
Parental Regimen
Preferred Regimen
Vancomycin 15 mg/kg IV q6h
OR
Linezolid 10 mg/kg IV q8h (max: 600mg/dose)
Alternative Regimen
Clindamycin 10-13 mg/kg IV q6-8h (max:40 mg/kg/day)
Oral Regimen
Preferred Regimen
Linezolid 10 mg/kg PO q8h (max: 600mg/dose)
OR
Clindamycin 10-13 mg/kg PO q6-8h (max:40 mg/kg/day)
Complicated cellulitis refers to a deeper soft-tissue infections and the association with necrotizing fasciitis, septic arthritis, or osteomyelitis

Note:

  • Treatment of cellulitis in neonates usually requires hospitalization and parenteral therapy. Oral therapy is given for completion of the treatment when the patogen is unknown.
  • Optimal dose should be based on determination of serum concentrations.
  • The above antibiotic regimen is NOT for initial empirical treatment of infections involving the face.
  • Dose alteration for renal insufficiency may be needed in case of cephalosporins.
  • Clindamycin is an alternate therapy for patients at risk of severe hypersensitivity reaction to penicillins and cephalosporins.
  • Doxycycline is NOT recommended for children <8 years of age.
  • Studies have shown an increase in treatment failure with TMP-SMX compared to other agents for cellulitis in children, reflecting TMP-SMX less action against Group A streptococcus.[3]


References

  1. Mathews, CJ.; Weston, VC.; Jones, A.; Field, M.; Coakley, G. (2010). "Bacterial septic arthritis in adults". Lancet. 375 (9717): 846–55. doi:10.1016/S0140-6736(09)61595-6. PMID 20206778. Unknown parameter |month= ignored (help)
  2. Dennis L. Stevens, Alan L. Bisno, Henry F. Chambers, E. Dale Everett, Patchen Dellinger, Ellie J. C. Goldstein, Sherwood L. Gorbach, Jan V. Hirschmann, Edward L. Kaplan, Jose G. Montoya & James C. Wade (2005). "Practice guidelines for the diagnosis and management of skin and soft-tissue infections". Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 41 (10): 1373–1406. doi:10.1086/497143. PMID 16231249. Unknown parameter |month= ignored (help)
  3. Elliott DJ, Zaoutis TE, Troxel AB, Loh A, Keren R (2009). "Empiric antimicrobial therapy for pediatric skin and soft-tissue infections in the era of methicillin-resistant Staphylococcus aureus". Pediatrics. 123 (6): e959–66. doi:10.1542/peds.2008-2428. PMID 19470525.